AtriCure, Inc. (ATRC) Soars to 52-Week High, Time to Cash Out?
AtriCure (ATRC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Has AtriCure (ATRC) Outpaced Other Medical Stocks This Year?
Here is how AtriCure (ATRC) and Ensign Group (ENSG) have performed compared to their sector so far this year.
AtriCure (ATRC) Is Up 6.32% in One Week: What You Should Know
Does AtriCure (ATRC) have what it takes to be a top stock pick for momentum investors? Let's find out.
ATRC Treats First Patients Using Novel Dual-Energy PFA-RFA Platform
AtriCure's first patients treated with its dual-energy PFA-RFA platform mark a key step as it moves toward a clinical trial next year.
Are Medical Stocks Lagging AtriCure (ATRC) This Year?
Here is how AtriCure (ATRC) and Boston Scientific (BSX) have performed compared to their sector so far this year.
Is AtriCure Stock a Buy or Sell After a Director Dumped 10,000 Shares?
AtriCure Board of Directors member Sven Wehrwein sold 10,000 shares in the company on Nov. 24 and 25, 2025. The transaction was valued at nearly $377,000.
Wall Street Analysts Believe AtriCure (ATRC) Could Rally 36.3%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 36.3% in AtriCure (ATRC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Is AtriCure (ATRC) Stock Outpacing Its Medical Peers This Year?
Here is how AtriCure (ATRC) and Cidara Therapeutics (CDTX) have performed compared to their sector so far this year.
AtriCure, Inc. (ATRC) Presents at UBS Global Healthcare Conference 2025 Transcript
AtriCure, Inc. ( ATRC ) UBS Global Healthcare Conference 2025 November 10, 2025 2:00 PM EST Company Participants Angela Wirick - Chief Financial Officer Michael H. Carrel - CEO, President & Director Conference Call Participants Danielle Antalffy - UBS Investment Bank, Research Division Presentation Danielle Antalffy UBS Investment Bank, Research Division Well, good afternoon, everyone.
AtriCure (ATRC) Loses 13.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for AtriCure (ATRC) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Here's What Key Metrics Tell Us About AtriCure (ATRC) Q3 Earnings (Revised)
While the top- and bottom-line numbers for AtriCure (ATRC) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Is AtriCure (ATRC) Outperforming Other Medical Stocks This Year?
Here is how AtriCure (ATRC) and Cabaletta Bio, Inc. (CABA) have performed compared to their sector so far this year.
